Lipella Pharmaceuticals, Inc. (LIPO, Financial) will feature its research on LP-10, a treatment for Oral Lichen Planus (OLP), at the upcoming 2025 international conference of the American Academy of Oral Medicine (AAOM) and the European Association of Oral Medicine (EAOM). The event is scheduled in Las Vegas from May 14 to 17.
The company's abstract on LP-10 has been selected for a podium presentation. This highlight underscores the potential impact of LP-10 in addressing OLP, a chronic inflammatory condition affecting the mouth. The presentation will be delivered by Dr. Alessandro Villa, who is the Chief of Oral Medicine, Oral Oncology, and Dentistry, and a Professor at the Herbert Wertheim College of Medicine, Miami Cancer Institute, on May 15.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Lipella Pharmaceuticals Inc (LIPO, Financial) is $10.00 with a high estimate of $10.00 and a low estimate of $10.00. The average target implies an upside of 317.54% from the current price of $2.40. More detailed estimate data can be found on the Lipella Pharmaceuticals Inc (LIPO) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Lipella Pharmaceuticals Inc's (LIPO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
